Ignite Creation Date:
2024-05-06 @ 3:59 AM
Last Modification Date:
2024-10-26 @ 11:41 AM
Study NCT ID:
NCT02421939
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-24
First Post:
2015-04-16
Brief Title:
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia AML With FMS-like Tyrosine Kinase FLT3 Mutation
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-10-20
Start Date Type:
ACTUAL
Primary Completion Date:
2018-09-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-07-31
Completion Date Type:
ESTIMATED
First Submit Date:
2015-04-16
First Submit QC Date:
April 16 2015
Study First Post Date:
2015-04-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2019-10-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-16
Last Update Post Date:
2024-06-24
Last Update Post Date Type:
ACTUAL